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Abstract: Hospital-acquired pneumonia (HAP) is a frequent cause of nosocomial infections,
responsible for great morbidity and mortality worldwide. The majority of studies on HAP have
been conducted in patients hospitalized in the intensive care unit (ICU), as mechanical ventilation
represents a major risk factor for nosocomial pneumonia and specifically for ventilator-associated
pneumonia. However, epidemiological data seem to be different between patients acquiring HAP in
the ICU vs. general wards, suggesting the importance of identifying non ICU-acquired pneumonia
(NIAP) as a clinical distinct entity in terms of both etiology and management. Early detection
of NIAP, along with an individualized management, is needed to reduce antibiotic use and side
effects, bacterial resistance and mortality. The present article reviews the pathophysiology, diagnosis,
treatment and prevention of NIAP.
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1. Search Strategy and Selection Criteria
We searched Medline for papers published from 1 January 2000 to 31 October 2015. We used the
search terms “hospital-acquired pneumonia” or “nosocomial pneumonia”, in combination with the
terms “epidemiology”, “diagnosis”, “aetiology”, “pathophysiology”, “risk factors”, “management”,
“treatment”, “outcomes”, “prevention”, and their variations. We restricted the search strategy to adults.
We also searched the reference lists of articles identified by this search strategy. Review articles and
book chapters are cited to provide readers with more details and more references. Among studies
found with this search strategy, we included only those including patients with hospital-acquired
pneumonia according to American Thoracic Society/Infectious Diseases Society of America ATS/IDSA
guidelines criteria, and who were hospitalized in both medical and surgical wards. Studies on patients
hospitalized in intensive care units were excluded. Studies providing data from a mixed population
(both intensive care units and general wards patients) were also excluded.
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2. Introduction
Hospital-acquired pneumonia (HAP) is the second most important cause of nosocomial infections
and accounts for high morbidity and mortality worldwide [1–3]. HAP also carries a relevant economic
burden on healthcare services and resources [4–6].
HAP is currently defined as pneumonia occurring at least 48 h after hospital admission and did
not appear to be incubating at the time of admission [2,6]. “HAP—Nosocomial pneumonia” specifically
identifies three different types of pneumonia: (1) ventilator-associated pneumonia (VAP), defined as
pneumonia developing more than 48 to 72 h after initiation of mechanical invasive ventilation; (2) non
ventilator-associated pneumonia in patients hospitalized in intensive care unit (ICU) (NV-ICUAP); and
(3) nosocomial pneumonia occurring in patients hospitalized in general wards outside of the ICU (non
ICU-acquired pneumonia -NIAP). Health-care associated pneumonia (HCAP) will not be considered
in this review according to recent microbiological data and the latest recommendations published by
the European Respiratory Society and the European Society of Clinical microbiology and Infectious
diseases [7–9].
The vast majority of studies on HAP included patients hospitalized in the ICU (either NV-ICUAP
or VAP). Evidence-based data on NIAP are largely extrapolated from experiences coming from the ICU
setting. Nevertheless, the absence of intubation and invasive mechanical ventilation could differentiate
the etiology and physiopathology of NV-ICUAP/VAP vs. NIAP, suggesting that the microbiology
and therapeutic approaches in these two diseases might be different. Thus, there is a clear need of
reviewing the available data on NIAP, in order to better identify, treat and eventually prevent the
development of this specific disease [10–15], see Table 1. We included studies specifically enrolling
adult patients with HAP hospitalized in general wards. Studies performed in the ICU or including a
mixed population of ICU and ward patients were excluded, see Figure 1.
The purpose of this review is to evaluate current evidence on pathogenesis, diagnosis, treatment,
and prevention of NIAP and to identify specific research needs in this field.
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3. Epidemiology
The global incidence of HAP is around 5–10 episodes per 1000 hospital admissions [3] and it is
higher among patients requiring mechanical ventilation, ranging between 10 and 15 cases per 1000
ventilator days [2]. The incidence of NIAP has not been fully evaluated in literature in light of a lack
of detection of cases in general wards, absence of defined diagnostic protocols and the difficulty in
obtaining samples for etiological diagnosis. Most of the available data come for studies enrolling a
mixed population of patients who developed a nosocomial pneumonia either in the ICU or general
wards (incidence ratio of 0.5–2 per 100 patients) or those who underwent thoracic or abdominal surgery
(incidence ratio of 3.8–17.5 per 100 patients), immunosuppressed patients (incidence ratio of 19.5–20
per 100 patients) or the elderly (incidence ratio of 0.7–1.7 per 100 patients) [16]. The incidence of NIAP
reported from the few studies conducted only in patients admitted to the general wards ranges from
1.6 to 3.67 cases per 1000 admissions [10–15].
Together with other types of HAP, NIAP is the most frequent cause of death among nosocomial
infections worldwide. Mortality rates range from 20% to 70%, depending on patient underlying
conditions and causative pathogen [10–15].
4. Risk Factors for NIAP
The most common risk factors for NIAP include advanced age, the presence and severity
of underlying diseases, such as chronic renal failure, anemia, neoplasm and chronic obstructive
pulmonary disease (COPD), malnutrition, depression of consciousness and nosocomial infections or
hospital admissions in the previous month, see Table 2 [10,11,15]. These characteristics increase the
patients’ risk of aspiration of contaminated respiratory or gastric secretions and decrease patients’
defenses. A study identified serum albumin level as an independent predictor of HAP in patients
with stroke, confirming patient’s nutritional status as an important feature that should be evaluated in
hospitalized patients to avoid nosocomial pneumonia [17].
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Table 1. Available literature on non ICU-acquired pneumonia (NIAP).
Author Year ofPublication Study Study Setting Number of pts Enrolled
Incidence/Prevalence
of NIAP
Most Frequent Pathogens
Isolated in NIAP
Sopena et al. [10] 2014 Incident case-controlstudy
Spain, 600-bed
tertiary hospital
119 cases with NIAP and
238 controls
2.45 cases/1000 hospital
admissions
S. pneumoniae 13%,
Enterobacteriaceae 8%,
P. aeruginosa 3%, MRSA 3%
Herer et al. [15] 2009 Randomized control trial France, 411-bed facility 68 pts with NIAP / Staphylococcus aureus 25.4%,MSSA 25%, P. aeruginosa 19%
Weber et al. [14] 2007 Prospective,observational study
USA, a tertiary care
academic hospital
556 pts (588 episodes of
pneumonia):
VAP 309 pts (327 episodes)
NIAP 247 pts (261 episodes)
/
Gram-positive cocci
(42.59% [MSSA, 13.33%];
[MRSA, 20.37%]),
P. aeruginosa 9%
Barreiro-Lopez et al. [13] 2005 Prospective case-controlstudy Spain 67 pts with NIAP
3.35 cases/1000
admissions /
Sopena et al. [11] 2005 Multicenter, prospective,observational study
Spain, 12 teaching
hospitals 186 patients with NIAP
3 ˘ 1.4 cases/1000
hospital admissions
S. pneumoniae, 9.7%,
Enterobacteriaceae 5%,
P. aeruginosa 4%
Everts et al. [12] 2000 Prospectiveobservational study
New Zealand,
university-affiliated
hospital
126 pts with NIAP 6.1 cases/1000admissions Legionella spp., 13%, MSSA 3%
pts: patients; NIAP non ICU acquired pneumonia, ICU intensive care unit, VAP ventilator associated pneumonia, MSSA methicillin sensitive S. aureus, MRSA methicillin resistant
S. aureus.
Table 2. Risk factors of infection with specific pathogens.
Penicillin-Resistant
Pneumococci Age > 65 years Betalactam-Therapy (last 3 month) Alcoholism Immune Suppressive Illness Multiple Comorbidities
Gram-negative bacilli Chronic underlying disease Multiple comorbidities Residence in a NH Recent antibiotic therapy
P. aeruginosa and multi resistant
Gram-negative bacilli Wide spectrum antibiotics Severe underlying disease Prior broad spectrum abt therapy Structural lung disease Corticosteroid therapy
Legionella Hospital potable water Previous nosocomial Legionellosis - - -
Anaerobes Gengivitis or periodontal disease Swallowing disorders Depressed consciousness Orotracheal manipulation -
MRSA Intravascular devices Nasal carriage High prevalence - -
Aspergillus Corticosteroid therapy Neutropenia Transplantation - -
NH nursing home, MRSA methicillin-resistant S. aureus.
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Beyond risk factors related to patient’s performance status, other risk factors for NIAP could
be identified, including therapeutic procedures, such as thoracic or upper abdominal surgery, the
use of nasogastric tubes, immunosuppressive treatment, previous antibiotic treatment, the length
of hospitalization and the use of acid suppressive medication [10,11,18]. Notably, the association
with HAP seems to be more significant for proton-pump inhibitors than histamine-2 receptor
antagonists [18].
Risk factors for increased mortality include severe underlying conditions, bilateral involvement,
the presence of sepsis, respiratory failure or multi-organ failure, an inappropriate initial antimicrobial
therapy and infections due to multi-drug resistant (MDR) microorganisms [10].
5. Physiopathology
Different mechanisms may contribute to the development of HAP, such as aspiration of upper
respiratory tract secretions, inhalation of contaminated aerosols and, more rarely, haematogenous
dissemination from septic foci, see Figure 2 [19]. Previous studies clearly recognized microaspiration
of contaminated oropharyngeal or gastric secretions (colonized by pathogenic bacteria) as the main
causative mechanism [3–5,8]. Subclinical microaspiration may be induced by depressed consciousness,
disorders in swallowing and cough reflex, or alterations in gastrointestinal motility. Microorganisms
in the oropharyngeal flora are the cause of pneumonia. After a few days from hospital admission,
bacterial flora shifts to Gram-negative bacilli, especially if patients are malnourished, severely ill or
already under antibiotic treatment [2,10]. Furthermore, the inhalation of aqueous (showers and water
taps) or airborne aerosols (dust or saliva drops) has been identified as possible, although uncommon,
cause of pneumonia sustained by specific microorganisms such as Legionella spp., Aspergillus spp.,
Chlamydia pneumoniae and virus [3]. Inadequate hand washing by medical personnel could also
facilitate the spread of resistant bacteria among patients [19]. Most of these data come from studies
that enrolled patients with HAP in general, while specific aspects of NIAP physiopathology have not
been explored yet.
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6. Causative Pathogens
The pathogens causing NIAP may vary, usually depending on different factors, including time of
pneumonia onset, previous patient health status, previous antibiotic therapy, residence in a nursing
home and finally the available diagnostic techniques used to identify these microorganisms. As far
as we know, etiology of nosocomial pneumonia could be different in NV-ICUAP/VAP vs. NIAP.
Unfortunately, most of the microbiological data available for nosocomial pneumonia are primarily
derived from studies performed in the ICU [3,4], see Table 1.
The oropharyngeal flora of non-ventilated patients admitted to the general wards may remain
unaltered for a long period of time, in comparison to what happens in mechanically ventilated patients
or those admitted to the ICU. Therefore, NIAP pathogens might mainly resemble those causing
community-acquired pneumonia, such as Streptococcus pneumoniae and Staphylococcus aureus [10,14].
Time of onset is also a crucial factor that deserves to be carefully considered. Early-onset
pneumonia is usually caused by community-acquired pathogens such as Haemophilus influenzae,
S. pneumoniae, or methicillin-susceptible S. aureus (MSSA) [11]. Pneumonia that develops after five
days from hospitalization (“late onset”) is often caused by aerobic Gram-negative bacilli (P. aeruginosa,
Enterobacteriaceae, or Acinetobacter) or methicillin-resistant S. aureus (MRSA) [2,11].
A careful evaluation of patient risk factors and comorbidities can also help to identify likely
causative pathogens of NIAP, see Table 2. Gram-negative bacilli are more prevalent in previously ill
patients, reflecting a switch in oropharyngeal flora, and among them the most frequent pathogens
are P. aeruginosa, A. baumannii, Enterobacteriaceae (Klebsiella spp., Enterobacter spp., Serratia spp., etc.)
and H. influenzae [10,11,14]. Prior antibiotics and hospitalizations could be more relevant than time
of onset [10]. Patients with none of the above characteristics have a much lower risk of harbouring a
highly resistant organism [10,11,14]. P. aeruginosa is more frequent in patients with severe underlying
illness (especially structural lung disease), prolonged hospitalization and wide spectrum antibiotic
therapy [7,8]. Moreover, the extensive use of third generation cephalosporins and fluoroquinolones
has increased the prevalence of Enterobacteria producing extended spectrum betalactamases (ESBLs),
such as Klebsiella pneumoniae, in the general wards [17,20]. S. aureus has been identified as predominant
causative pathogen in some studies among patients with NIAP [14,15]. MRSA is usually detected in
patients with specific risk factors, such as intravascular catheters, nasal carriage and staying in hospitals
and/or departments with a high prevalence of colonisation or infection by these microorganisms [3,18].
S. pneumoniae is recognized as a predominant causative agent of nursing home pneumonia [21]. In
addition, among the elderly, inadequate oral care and difficult swallowing are known risk factors
for aspiration pneumonia and anaerobes [22]. Microorganisms such as L. pneumophila, anaerobes
and viruses are not routinely tested in NIAP and thus, their prevalence is largely unknown [23].
Legionellosis could be diagnosed in immunocompromised patients or in local hospital outbreaks
because of contaminated water supplies. Immunocompromised patients or COPD patients receiving
systemic steroids could developed pneumonia by Aspergillus spp., caused by inhalation of fungal spores
from the environment (dust, furniture and ornamental plants), food products or even water [11,18,24].
Rarely, viruses, Mycobacterium tuberculosis, Mycoplasma pneumoniae or Chlamydia pneumoniae could be
causative pathogens of nosocomial pneumonia [14,15,25].
7. Clinical Presentation and Diagnosis
The clinical presentation of NIAP is not specific. Patients usually present with fever and
respiratory symptoms, such as new onset or worsening cough and expectoration with purulent sputum.
Dyspnoea and pleuritic chest pain are less frequent and may be caused by other underlying conditions.
Moreover, patients with neurological impairment or severe illness may be unable to manifest or express
these symptoms. On physical examination, tachypnoea, rales or bronchial breathing sounds may be
present, although their detection may often be difficult in patients with underlying diseases [3,10].
Chest radiography (CXR) demonstrates new or progressive infiltrates, consolidation, cavitation or
pleural effusion. Differential diagnosis should be made with other processes which may cause similar
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clinical and radiological changes, including heart failure, pulmonary embolism, ARDS, atelectasis,
alveolar haemorrhage, or lung contusions [3]. Diagnosis of HAP is based on the appearance of a
pulmonary infiltrate on CXR at least 48 h after hospital admission, which is not attributable to any
other cause. The presence of at least two of the three following clinical features is also required: fever,
leukocytosis or leukopenia and/or purulent respiratory secretions [4,18]. However, these criteria
are not very sensitive and specific, particularly in the elderly, immunosuppressed patients or those
with cardiopulmonary diseases. Moreover, CXR may lead to misdiagnosis, as it lacks sensitivity and
specificity, compared to chest CT scan [26].
8. Microbiological Evaluation
Etiological diagnosis of NIAP is usually based on results of blood cultures, urinary antigens and
sputum or tracheal secretions, because of the inability to perform invasive procedures in most cases.
Use of invasive techniques to achieve an etiologic diagnosis is less common among NIAP patients in
comparison to those with VAP/NVICUAP. The diagnosis of VAP can be based on either clinical findings
or results of invasive methods, such as protected specimen brush (PSB), or bronchoalveolar lavage
(BAL) [15]. An invasive strategy based on quantitative bronchoscopic specimen culture improves
early survival among VAP patients [27], but it is unknown whether this strategy is beneficial for
NIAP patients.
The use of invasive diagnostic strategies for NIAP may have several disadvantages, including
high costs and significant morbidity. Non-invasive management of HAP may nevertheless have
potentially harmful consequences: inadequate treatment leading to higher mortality risk, patients may
receive unnecessary or potentially toxic antibiotics, resistant microorganisms may be selected, and
diagnosis of a non-infectious cause of fever and pulmonary infiltration may be delayed [15].
Bronchoscopy with BAL should always be considered in immunosuppressed patients or those
who do not improve after 48–72 h of empiric antibiotic treatment. A patient is considered to have
pneumonia when culture reveals more than 1 ˆ 104 organisms/mL with standard BAL. It has been
shown that invasive procedures lead to less antibiotic overuse [15].
9. Biomarkers
Biomarkers of infection and sepsis, such as procalcitonin (PCT) and C-reactive protein (CRP),
could be used for the diagnosis and management of respiratory tract infections [28]. They may be
applied as rapid and accurate tools to determine the possible presence of infection and, thus, avoid
antibiotic overuse. Furthermore, a soluble triggering receptor expressed on myeloid cells (sTREM-1)
that is up-regulated in the setting of infection has been shown to have a role in identifying pneumonia.
However, further studies are needed before this marker may be employed in routine clinical practice.
10. Treatment
A delay in administrating effective antibiotics in patients with suspected NIAP may impact their
prognosis. Thus, patients should be treated immediately with antimicrobials without waiting for
microbial results, even when the patient is clinically stable [1–5,29].
In order to choose the most effective empirical therapy, clinicians must take into account several
factors, including the severity of pneumonia, risk factors associated with specific pathogens and the
time of pneumonia onset [30]. In addition, it is crucial to know the predominant pathogens in a
specific clinical setting, as well as the local antibiotic susceptibilities. There are significant geographical
differences in the frequencies of antimicrobial resistance between some European areas and even
within the same country, from one hospital to another. Therefore, pathogen and susceptibility patterns
should be regarded primarily as potential indicators of general trends and lead to increased attention to
the local epidemiology. It is now established that each antimicrobial treatment policy shows a specific
selective pressure. Consequently, each local setting recognizes a specific ecological and resistance
patterns due to previous and current policies. Therefore, it is clear that recommendations for initial
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empiric antimicrobial treatment should acknowledge a sufficient flexibility to allow modifications
according to local peculiarities [2], which are usually the result of preventive and treatment strategies
and the type of population treated.
According to some authors, four categories of nosocomial pneumonia in non-ventilated patients
could be distinguished: (1) severe NIAP; (2) NIAP with risk factors; (3) early-onset NIAP and
(4) late-onset NIAP [30], see Figure 3.
Int. J. Mol. Sci. 2016, 17, 287 8 of 14 
 
cc r i  to some authors, four categories of nosocomial p eumonia in non-ventilated 
patients could be distinguished: (1) severe NIAP; (2) NIAP with risk factors; (3) early-onset NIAP 
and (4) late-onset NIAP [30], see Figure 3. 
 
Figure 3. Categories of non ICU acquired pneumonia (NIAP). 
Severity is defined by the presence of extensive or progressive radiological involvement, 
respiratory failure, sepsis, and/or severe organ dysfunction. The most frequent pathogens in severe 
NIAP are S. pneumoniae, P. aeruginosa, Enterobacteriaceae, see Figure 4. Some characteristics could be 
risk factors for infections by specific pathogens and should be taken into account when deciding 
empirical antibiotic therapy in patients with moderate-mild NIAP, see Table 2. In patients with none 
of these risk factors, time of onset of pneumonia is the main variable to guide the empirical therapy. 
 
Figure 4. Etiologic pathogens according to categories of non-ICU acquired pneumonia (NIAP). 
In case of severe pneumonia or if MDR pathogens are suspected, a combined empirical therapy 
is suggested in order to prevent the development of resistance during treatment, see Table 3. 
  
Figure 3. Categories of non ICU acquired pneumonia (NIAP).
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In case of severe pneumonia or if MDR pathogens are suspected, a combined empirical therapy is
suggested in order to prevent the development of resistance during treatment, see Table 3.
Table 3. Treatment of non ICU-acquired pneumonia (NIAP).
Beta-lactams *
+
aminoglycoside
Or
quinolone
SEVERE NIAP
NIAP WITH RISK FACTORS FOR
P. aeruginosa
Gram negative bacilli
Antipseudomonal cephalosporin
Or
Fluoroquinolones
LATE ONSET NIAP
<5 days
Beta-lactam/beta-lactamase inhibitor
Or
Third generation non-pseudomonal cephalosporin:
Or
Fluoroquinolones
EARLY ONSET NIAP
<5 days
Levofloxacin
Or
azitromycin
LEGIONELLA SPP:
Carbapenems
Or
b-lactam/b-lactamase inhibitor
ANAEROBES
Vancomycin
Or
Linezolid
MRSA (Methicillin resistant S. aureus)
Amphotericyn B desoxicolate
Or
amphotericyn liposomal
Or
Voriconazol
ASPERGILLUS SPP.
* include: antipseudomonal cephalosporin, antipseudomonal carbapenem and beta-lactam/
beta-lactamase inhibitor.
10.1. De-Escalation and Withdrawal
Once microbiological results become available, antimicrobial therapy may be modified, either
narrowing/broadening the antibiotic spectrum or selecting a pathogen-directed antibiotic therapy
or even discontinuing antibiotics if pneumonia is ruled out [3,30], see Figure 5. Experts suggest that
treatment could be discontinued if the following three criteria are fulfilled: (1) clinical diagnosis of
pneumonia is unlikely (no definite infiltrates on CXR at follow-up and no more than one of the three
following findings: temperature >38.3 ˝C, leukocytosis or leukopenia, and purulent tracheobronchial
secretions) or an alternative non-infectious diagnosis is confirmed; (2) tracheobronchial aspirate
culture results are non-significant; and (3) there is no evidence of severe sepsis or septic shock [30].
Some studies also indicate that serial measurements of PCT could be a helpful marker in deciding
to discontinue antibiotics and, thus, reducing antibiotic use. However, further studies are needed to
validate these data [31].
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Figure 5. anagement strategies for a patient with suspected non ICU acquired pneumonia (NIAP).
10.2. Response to Treatment
Treatment should be considered effective in case of remission of fever, reduction in sputum
production and purulence, reduction of leukocytosis, improvement of hypoxaemia, and resolution
of possible organ dysfunctions within 48–72 h after initiation of antibiotic therapy. Treatment
response could be delayed in patients with severe pneumonia, with more virulent pathogens or
in more debilitated patients. Finally, treatment failure could be due to several causes, including:
(1) non-infectious aetiology; (2) severe pre-existing host conditions (e.g., underlying diseases, older
age, chronic lung diseases and immunosuppression); (3) multi-drug resistant (MDR) microorganisms
and (4) infectious complications, such as empyema or pulmonary abscess.
10.3. uration of Therapy
uration of antibiotic therapy is not ell defined in patients ith lo er respiratory tract
infection [32,33]. Usually, if pneumonia is sustained by pathogens such as S. pneumoniae, H. influenzae
or methicillin-sensitive S. aureus, 7 to 10 days of treatment might be sufficient. On the other hand,
pneumonia caused by other resistant microorganis s treatment should be prolonged to at least 14–21
days. However, most of the indications on duration of antibiotic therapy with patients with pneumonia
are based on experts’ opinions [32,33].
Prevention
i i
ti s and specifically of nosocomial pneumonia, w th subsequent important clinical and financial
consequences, see Table 4. Unfortunately, the majority of studies focused on preventing strategies were
carri d out in ICU patients, with the majority of being on invasiv mecha ic l ntilatio [6].
Thus, specific preventiv strategies targ ted for NIAP haven’t been developed yet.
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Table 4. Overview of NIAP vs. VAP/NV-ICUAP.
NIAP VAP/NVICUAP
Diagnosis
New infiltrate on CXR after 48 h of
hospital admission +:
fever,
dyspnea,
cough and purulent expectoration,
leukocytosis or leukopenia
New or worsening infiltrates on CXR
after 48 h after initiation of invasive
mechianical ventilation/admission to
ICU admission +
fever
worsening of PaO2/FiO2
purulent tracheal secretions
leukocytosis or leukopenia
Stratification
Severe NIAP
NIAP with risk factors
Early onset NIAP
Late onset NIAP
Ventilated patient/spontaneously
breathing patient
Late vs. early onset
Presence of risk factors
Microbiological tests
Blood cultures
Urinary Antigens
Sputum
Tracheal aspirate
Blood cultures
PBS
BAL
BAS
Etiology
S. pneumoniae
Enterobacteriaceae
P. aeruginosa
S. aureus
Legionella pn.
Early onset: S. aureus, S. pneumoniae,
H. influenzae, non-drug resistant GNEB
Late onset: MRSA, drug resistant GNEB,
P. aeruginosa, A. baumannii
Empirical therapy
Severe NIAP: b-lactams with an
aminoglycoside or fluoroquinolone
Early onset NIAP:
b-lactam/b-lactamase inhibitor or third
generation non-pseudomonal
cephalosporin, or fluoroquinolones
Late onset NIAP: Antipseudomonal
cephalosporin Fluoroquinolones
NIAP with risk factors: specific for
each organism
Early onset:
aminopenicillin plus
b-lactamase-inhibitor Or third
generation cephalosporin Or quinolones
Late onset:
antipseudomonal penicillin Or
antipseudomonal cephalosporin Or
carbapenems
Plus quinolone
if MRSA suspected
Vancomycin Or Linezolid
Antimicrobial treatment of pneumonia
with risk factors, any onset: specific for
each organism
Prevention
Interventions to modify individual risk
factors, such as malnutrition, anemia,
and risk of aspiration
Hand hygiene
Isolation of MDR patients
Avoid intubation
Semi-recumbent position to decrease
aspiration of oropharyngeal secretions
Oral hygiene with chlorhexidine
Probiotics
Specialized endotracheal tubes
(subglottic secretion drainage;
silvercoated)
In-hospital mortality One third of cases
20% to 70%, depending on the
characteristics of the patient and the
microorganism involved
Table legend: NIAP non ICU-acquired pneumonia, VAP ventilator associated pneumonia, NV-ICUAP non
ventilator ICU acquired pneumonia, CXR chest X ray, ICU intensive care unit, PBS protected specimen brush,
BAL bronchoalveolar lavage, BAS bronchial aspirate, GNEB gram negative Enteric Bacilli, MRSA methicillin
resistant S. aureus.
General measures for infection control include alcohol-based hand disinfection, the use of
microbiologic surveillance, monitoring and early removal of invasive devices and programs to reduce
antimicrobial prescriptions [2,16,34–36]. Awareness of the physiopathology of nosocomial pneumonia
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has led to the development of specific preventive strategies, e.g., to reduce oropharyngeal colonization,
cross-contamination from other patients and from the environment and, when possible, correct
individual risk factors, such as aspiration [35,37–39]. The management of malnutrition is also crucial,
as hypoalbuminaemia has been identified as a risk factor for HAP [17]. The use of immunosuppressive
drugs, wide-spectrum antibiotics and nasogastric tubes should be avoided, when possible. Finally,
each centre should have a nosocomial infection control program in order to improve prevention and
management of NIAP, as well as other nosocomial infections.
12. Conclusions and Research Needs
Most of the available data on nosocomial pneumonia derive from studies on mechanically
ventilated patients. In contrast, there are very few data on NIAP. Our review highlighted some
important points that need to be developed in further trials and studies, see Table 4.
First of all, the exact incidence of NIAP is unknown, due to the lack of defined diagnostic criteria
and insufficient surveillance of this disease in general wards, in comparison to VAP or NV-ICUAP.
Clinicians should monitor suspected NIAP in patients hospitalized in general wards, in order to achieve
prompt identification of this disease, to evaluate more precisely its incidence and to better describe
its extent and impact on both patients’ prognosis and health care system resources. Subsequently, a
diagnostic path should be designed, based on clinical, laboratory, radiological and microbiological
data, following a multidisciplinary approach and involving clinicians, intensivists, microbiologists,
pharmacists, and infection-control professionals. In particular, microbiological protocols should be
developed in order to obtain adequate and standardized samples, to rule out or confirm the diagnosis of
NIAP and to identify the most likely causative pathogens. Being aware of the most probable causative
pathogens could allow clinicians to remove some known risk factors for this disease and to choose the
most effective antibiotic strategy. Moreover, de-escalating and shortening the antibiotic therapy are
relevant approaches to decrease the emergence of resistant strains and therefore to minimize treatment
failure. Finally, the impact of lower respiratory tract infections on medium and long-term outcomes,
including cardiovascular events, is well known in community-acquired pneumonia, while data on
nosocomial pneumonia and NIAP are urgently needed [40,41].
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